Chapter 1. Introduction


1.1. Report description and scope

1.2. Research scope

1.3. Research methodology


1.3.1. Market research process

1.3.2. Market research methodology

Chapter 2. Executive Summary


2.1. Global Immuno-oncology Therapy Market, 2016 2022 (USD Billion)

2.2. Global Immuno-oncology Therapy Market: Snapshot

Chapter 3. Immuno-oncology Therapy Market Market Dynamics


3.1. Introduction

3.2. Market Drivers


3.2.1. Global immuno-oncology therapy market drivers: Impact analysis

3.2.2. Highly Promising Treatment Pipeline

3.2.3. Increase in Number of Patients Suffering from Various Cancers

3.2.4. Greater Efficiency Over Conventional Treatment Methods

3.3. Market Restraints


3.3.1. Global immuno-oncology therapy market restraints: Impact analysis

3.3.2. High Level of Attrition within the Development Cycles

3.3.3. Stringent Regulatory Framework

3.3.4. Lack of Awareness of Immunotherapy

3.4. Opportunities


3.4.1. Developed Economies Showing Higher Development Rates

3.5. Porters five forces analysis


3.5.1. Bargaining power of suppliers

3.5.2. Bargaining power of buyers

3.5.3. Threat from new entrants

3.5.4. Threat from new substitutes

3.5.5. Degree of competition

3.6. Market attractiveness analysis


3.6.1. Market attractiveness analysis, by therapy type segment

3.6.2. Market attractiveness analysis, by end-user segment

3.6.3. Market attractiveness analysis, by regional segment

Chapter 4. Global Immuno-oncology Therapy Market Competitive Landscape


4.1. Company Market Share Analysis


4.1.1. Global immuno-oncology therapy market: company market share, 2016

4.2. Strategic Development


4.2.1. Acquisitions Mergers

4.2.2. New Therapy Launch

4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures

4.2.4. Research and Development and Regional Expansion

4.3. Price Trend Analysis

Chapter 5. Global Immuno-oncology Therapy Market Therapy Type Segment Analysis


5.1. Global immuno-oncology therapy market: therapy type overview


5.1.1. Global immuno-oncology therapy market revenue share, by therapy type, 2016 and 2022

5.2. Monoclonal Antibodies


5.2.1. Global immuno-oncology therapy market for monoclonal antibodies market, 2016 2022 (USD Billion)

5.3. Immune Checkpoint Inhibitors


5.3.1. Global immuno-oncology therapy market for immune checkpoint inhibitors market, 2016 2022 (USD Billion)


5.3.1.1. Global immuno-oncology therapy market for PD1/ PDL1 market, 2016 2022 (USD Billion)

5.3.1.2. Global immuno-oncology therapy market for CTLA-4 market, 2016 2022 (USD Billion)

5.4. Immune System Modulators


5.4.1. Global immuno-oncology therapy market for immune system modulators market, 2016 2022 (USD Billion)

5.5. Cancer Vaccines


5.5.1. Global immuno-oncology therapy market for cancer vaccines market, 2016 2022 (USD Billion)

5.6. Others


5.6.1. Global immuno-oncology therapy market for others market, 2016 2022 (USD Billion)

Chapter 6. Global Immuno-oncology Therapy Market Therapeutic Area Segment Analysis


6.1. Global immuno-oncology therapy market: therapeutic area overview


6.1.1. Global immuno-oncology therapy market revenue share, by therapeutic area, 2016 and 2022

6.2. Lung Cancer


6.2.1. Global immuno-oncology therapy market for lung cancer market, 2016 2022 (USD Billion)

6.3. Colorectal Cancer


6.3.1. Global immuno-oncology therapy market for colorectal cancer market, 2016 2022 (USD Billion)

6.4. Breast Cancer


6.4.1. Global immuno-oncology therapy market for breast cancer market, 2016 2022 (USD Billion)

6.5. Prostate Cancer


6.5.1. Global immuno-oncology therapy market for prostate cancer market, 2016 2022 (USD Billion)

6.6. Melanoma


6.6.1. Global immuno-oncology therapy market for melanoma market, 2016 2022 (USD Billion)

6.7. Blood Cancer


6.7.1. Global immuno-oncology therapy market for blood cancer market, 2016 2022 (USD Billion)

6.8. Other Cancers


6.8.1. Global immuno-oncology therapy market for other cancers market, 2016 2022 (USD Billion)

Chapter 7. Global Immuno-oncology Therapy Market End-User Segment Analysis


7.1. Global immuno-oncology therapy market: end-user overview


7.1.1. Global immuno-oncology therapy market revenue share, by end-user, 2016 and 2022

7.2. Hospitals


7.2.1. Global immuno-oncology therapy market for hospitals 2016 2022 (USD Billion)

7.3. Clinics


7.3.1. Global immuno-oncology therapy market for clinics, 2016 2022 (USD Billion)

7.4. Ambulatory Surgical Centers (ASCs)


7.4.1. Global immuno-oncology therapy market for ambulatory surgical centers, 2016 2022 (USD Billion)

7.5. Cancer Research Institutes

7.5.1. Global immuno-oncology therapy market for cancer research institutes end-users, 2016 2022 (USD Billion)

Chapter 8. Global Immuno-oncology Therapy Market Regional Segment Analysis


8.1. Global immuno-oncology therapy market: regional overview


8.1.1. Global immuno-oncology therapy market revenue share, by region, 2016 and 2022

8.2. North America


8.2.1. North America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.2.2. North America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.2.3. North America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.2.4. U.S.


8.2.4.1. U.S. Immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.2.4.2. U.S. Immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.2.4.3. U.S. Immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.2.5. Canada


8.2.5.1. Canada immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.2.5.2. Canada immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.2.5.3. Canada immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.2.6. Rest of North America


8.2.6.1. Rest of North America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.2.6.2. Rest of North America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.2.6.3. Rest of North America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.3. Europe


8.3.1. Europe immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.3.2. Europe immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.3.3. Europe immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.3.4. U.K.


8.3.4.1. U.K. Immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.3.4.2. U.K. Immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.3.4.3. U.K. Immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.3.5. Germany


8.3.5.1. Germany immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.3.5.2. Germany immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.3.5.3. Germany immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.3.6. France


8.3.6.1. France immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.3.6.2. France immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.3.6.3. France immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.3.7. Italy


8.3.7.1. Italy immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.3.7.2. Italy immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.3.7.3. Italy immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.3.8. Spain


8.3.8.1. Spain immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.3.8.2. Spain immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.3.8.3. Spain immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.3.9. Russia


8.3.9.1. Russia immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.3.9.2. Russia immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.3.9.3. Russia immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.3.10. Rest of Europe


8.3.10.1. Rest of Europe immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.3.10.2. Rest of Europe immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.3.10.3. Rest of Europe immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.4. Asia Pacific


8.4.1. Asia Pacific immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.4.2. Asia Pacific immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.4.3. Asia Pacific immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.4.4. China


8.4.4.1. China immuno-oncology therapy market revenue, by therapy type, 2016 2022(USD Billion)

8.4.4.2. China immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.4.4.3. China immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.4.5. Japan


8.4.5.1. Japan immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.4.5.2. Japan immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.4.5.3. Japan immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.4.6. India


8.4.6.1. India immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.4.6.2. India immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.4.6.3. India immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.4.7. Australia


8.4.7.1. Australia immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.4.7.2. Australia immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.4.7.3. Australia immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.4.8. Rest of Asia Pacific


8.4.8.1. Rest of Asia Pacific immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.4.8.2. Rest of Asia Pacific immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.4.8.3. Rest of Asia Pacific immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.5. Latin America


8.5.1. Latin America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.5.2. Latin America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.5.3. Latin America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.5.4. Brazil


8.5.4.1. Brazil immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.5.4.2. Brazil immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.5.4.3. Brazil immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.5.5. Mexico


8.5.5.1. Mexico immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.5.5.2. Mexico immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.5.5.3. Mexico immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.5.6. Argentina


8.5.6.1. Argentina immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.5.6.2. Argentina immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.5.6.3. Argentina immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.5.7. Rest of Latin America


8.5.7.1. Rest of Latin America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.5.7.2. Rest of Latin America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.5.7.3. Rest of Latin America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.6. Middle East and Africa


8.6.1. Middle East and Africa immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.6.2. Middle East and Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.6.3. Middle East and Africa immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.6.4. Saudi Arabia


8.6.4.1. Saudi Arabia immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.6.4.2. Saudi Arabia immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.6.4.3. Saudi Arabia immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.6.5. UAE


8.6.5.1. UAE immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.6.5.2. UAE immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.6.5.3. UAE immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.6.6. Qatar


8.6.6.1. Qatar immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.6.6.2. Qatar immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.6.6.3. Qatar immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.6.7. South Africa


8.6.7.1. South Africa immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.6.7.2. South Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.6.7.3. South Africa immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

8.6.8. Rest of Middle East and Africa


8.6.8.1. Rest of Middle East and Africa immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)

8.6.8.2. Rest of Middle East and Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)

8.6.8.3. Rest of Middle East and Africa immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)


Chapter 9. Company Profile


9.1. Amgen, Inc.


9.1.1. Overview

9.1.2. Financials

9.1.3. Therapy portfolio

9.1.4. Business strategy

9.1.5. Recent developments

9.2. AstraZeneca Plc.


9.2.1. Overview

9.2.2. Financials

9.2.3. Therapy portfolio

9.2.4. Business strategy

9.2.5. Recent developments

9.3. Bristol-Myers Squibb Company


9.3.1. Overview

9.3.2. Financials

9.3.3. Therapy portfolio

9.3.4. Business strategy

9.3.5. Recent developments

9.4. Eli Lilly and Company


9.4.1. Overview

9.4.2. Financials

9.4.3. Therapy portfolio

9.4.4. Business strategy

9.4.5. Recent developments

9.5. F.Hoffmann-La Roche Ltd.


9.5.1. Overview

9.5.2. Financials

9.5.3. Therapy portfolio

9.5.4. Business strategy

9.5.5. Recent developments

9.6. GlaxoSmithKline Plc.


9.6.1. Overview

9.6.2. Financials

9.6.3. Therapy portfolio

9.6.4. Business strategy

9.6.5. Recent developments

9.7. Janssen Biotech


9.7.1. Overview

9.7.2. Financials

9.7.3. Therapy portfolio

9.7.4. Business strategy

9.7.5. Recent developments

9.8. Merck and Co.


9.8.1. Overview

9.8.2. Financials

9.8.3. Therapy portfolio

9.8.4. Business strategy

9.8.5. Recent developments

9.9. Novartis AG


9.9.1. Overview

9.9.2. Financials

9.9.3. Therapy portfolio

9.9.4. Business strategy

9.9.5. Recent developments

9.10. Pfizer, Inc.


9.10.1. Overview

9.10.2. Financials

9.10.3. Therapy portfolio

9.10.4. Business strategy

9.10.5. Recent developments

9.11. Sanofi


9.11.1. Overview

9.11.2. Financials

9.11.3. Therapy portfolio

9.11.4. Business strategy

9.11.5. Recent developments

9.12. Spectrum Pharmaceuticals, Inc.


9.12.1. Overview

9.12.2. Financials

9.12.3. Therapy portfolio

9.12.4. Business strategy

9.12.5. Recent developments

9.13. Takeda Pharmaceuticals


9.13.1. Overview

9.13.2. Financials

9.13.3. Therapy portfolio

9.13.4. Business strategy

9.13.5. Recent developments